Durable response after cessation of anti‐programmed death 1 therapy in four melanoma patients

2019 ◽  
Vol 46 (12) ◽  
Author(s):  
Toshiya Handa ◽  
Junji Kato ◽  
Yasuyuki Sumikawa ◽  
Tokimasa Hida ◽  
Kohei Horimoto ◽  
...  
Keyword(s):  
Durable Response ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Melanoma Patients

Association of eosinophila with efficacy in non-melanoma patients treated with programmed death 1 inhibitors.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e14510-e14510
Author(s):  
Matthew R. Zibelman ◽  
Julia Judd ◽  
Elizabeth Handorf ◽  
John O'Neill ◽  
Sasini Bentota ◽  
...  
Keyword(s):  
Programmed Death ◽  
Programmed Death 1 ◽  
Melanoma Patients

scholarly journals ECG Changes in Melanoma Patients Undergoing Cancer Therapy—Data from the ECoR Registry

2020 ◽  
Vol 9 (7) ◽  
pp. 2060
Author(s):  
Julia Pohl ◽  
Raluca-Ileana Mincu ◽  
Simone Maria Mrotzek ◽  
Lena Hinrichs ◽  
Lars Michel ◽  
...  
Keyword(s):  
Heart Rate ◽  
Checkpoint Inhibitors ◽  
Qt Dispersion ◽  
Qtc Interval ◽  
Programmed Death ◽  
Before And After ◽  
Programmed Death 1 ◽  
Qrs Duration ◽  
Melanoma Patients ◽  
Electrocardiogram Ecg

We aimed to evaluate whether therapy with immune checkpoint inhibitors (ICI) leads to changes in electrocardiogram (ECG) parameters in melanoma patients. We retrospectively examined 41 patients (46% women, age 61 ± 12years) with advanced melanoma (stage III/IV) before and during ICI treatment from our “Essen Cardio-oncology Registry” (ECoR). ECGs were analyzed before and 4–12 weeks after therapy started (follow-up, 90 ± 51 days). Heart rate, PR time, QRS duration and duration of the corrected QT (QTc) interval were recorded. QT dispersion (QTd) was calculated. Heart rate, PR time, QRS and QTc did not differ when comparing values before and after therapy started. QTd was prolonged after therapy started (32 ± 16 ms vs. 47 ± 19 ms, n = 41, p < 0.0001). Subgroup analyses revealed prolonged QTd in patients that received a combination immunotherapy with ipilimumab and nivolumab (31 ± 14 ms vs. 50 ± 14 ms, n = 21, p < 0.0001), while QTd in patients with anti–programmed death 1 (PD-1) inhibitor monotherapy did not change after therapy started. QTd is prolonged in patients under ICI combination therapy, potentially signaling an increased susceptibility to ventricular arrhythmias.

scholarly journals Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody

2018 ◽  
Vol 109 (10) ◽  
pp. 3032-3042 ◽  
Author(s):  
Kyoko Yamaguchi ◽  
Koji Mishima ◽  
Hirofumi Ohmura ◽  
Fumiyasu Hanamura ◽  
Mamoru Ito ◽  
...  
Keyword(s):  
T Cells ◽  
Memory T Cells ◽  
Effector Memory ◽  
T Helper ◽  
T Helper 1 ◽  
Effector Memory T Cells ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Melanoma Patients ◽  
Central Effector

Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients

2017 ◽  
Vol 35 (6) ◽  
pp. 842-847 ◽  
Author(s):  
Valentine Heidelberger ◽  
François Goldwasser ◽  
Nora Kramkimel ◽  
Anne Jouinot ◽  
Nathalie Franck ◽  
...  
Keyword(s):  
Tumor Response ◽  
Clinical Parameters ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Melanoma Patients

scholarly journals Robotic Stereotactic Radiosurgery in Melanoma Patients with Brain Metastases under Simultaneous Anti-PD-1 Treatment

2018 ◽  
Vol 19 (9) ◽  
pp. 2653 ◽  
Author(s):  
Maike Trommer-Nestler ◽  
Simone Marnitz ◽  
Martin Kocher ◽  
Daniel Rueß ◽  
Max Schlaak ◽  
...  
Keyword(s):  
Acute Toxicity ◽  
Brain Metastases ◽  
Stereotactic Radiosurgery ◽  
Local Control ◽  
Lesion Size ◽  
Simultaneous Treatment ◽  
Volumetric Assessment ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Melanoma Patients

Combination concepts of radiotherapy and immune checkpoint inhibition are currently of high interest. We examined imaging findings, acute toxicity, and local control in patients with melanoma brain metastases receiving programmed death 1 (PD-1) inhibitors and/or robotic stereotactic radiosurgery (SRS). Twenty-six patients treated with SRS alone (n = 13; 20 lesions) or in combination with anti-PD-1 therapy (n = 13; 28 lesions) were analyzed. Lesion size was evaluated three and six months after SRS using a volumetric assessment based on cranial magnetic resonance imaging (cMRI) and acute toxicity after 12 weeks according to the Common Terminology Criteria for Adverse Events (CTCAE). Local control after six months was comparable (86%, SRS + anti-PD-1, and 80%, SRS). All toxicities reported were less than or equal to grade 2. One metastasis (5%) in the SRS group and six (21%) in the SRS + anti-PD-1 group increased after three months, whereas four (14%) of the six regressed during further follow-ups. This was rated as pseudoprogression (PsP). Three patients (23%) in the SRS + anti-PD-1 group showed characteristics of PsP. Treatment with SRS and anti-PD-1 antibodies can be combined safely in melanoma patients with cerebral metastases. Early volumetric progression of lesions under simultaneous treatment may be related to PsP; thus, the evaluation of combined radioimmunotherapy remains challenging and requires experienced teams.

Immune related adverse events as a biomarker in non-melanoma patients treated with programmed death 1 inhibitors (PD-1Is).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 3069-3069 ◽  
Author(s):  
Julia Judd ◽  
Matthew R. Zibelman ◽  
Elizabeth Handorf ◽  
John O'Neill ◽  
Sasini Bentota ◽  
...  
Keyword(s):  
Adverse Events ◽  
Programmed Death ◽  
Programmed Death 1 ◽  
Melanoma Patients
Sign in / Sign up

Export Citation Format

Share Document